Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the short-term efficacy and safety of intravitreal bevacizumab injections (IVB) for refractory choroidal neovascularization (CNV) secondary to uveitis.

Methods

Ten patients affected by choroidal neovascularization secondary to uveitis unresponsive to immunosuppression associated or not with photodynamic therapy (PDT) were consecutively included. All patients underwent a complete ophthalmic examination including best-corrected visual acuity (BCVA), fluorescein (FA) and indocyanine green angiographies (ICG), optical coherence tomography (OCT) at baseline, and after IVB injection (1.25 mg/0.05 ml).

Results

CNV was subfoveal in eight cases and juxtafoveal in two cases. Mean follow-up was 7.5 months. After treatment, the logMAR BCVA improved from 0.62 ± 0.4 (Snellen equivalent of 20/55) to 0.45 ± 0.35 (Snellen equivalent of 20/40) at 1 month (p = 0.01), then remained stable during the follow-up. Mean central macular thickness (CMT) was reduced from 326 ± 95 μm before treatment to 267 ± 28 μm (p = 0.03) at last visit. Mean number of IVB was 2.5. Leakage from inflammatory CNV was stopped in three eyes and decreased in seven eyes. No systemic or ocular adverse events were recorded.

Conclusions

Intravitreal bevacizumab improves BCVA and reduces central macular thickness in eyes with inflammatory CNV refractory to immunosuppression associated or not with PDT. Further study is necessary to assess the efficacy and safety in the long term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ (1998) The use of corticosteroids for choroidal neovascularisation in young patients. Eye 12(Pt 2):266–272

    PubMed  Google Scholar 

  2. Hogan A, Behan U, Kilmartin DJ (2005) Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 89:1109–1111, doi:10.1136/bjo.2004.063024

    Article  PubMed  CAS  Google Scholar 

  3. Thorne JE, Wittenberg S, Jabs DA, Peters GB, Reed TL, Kedhar SR et al (2006) Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. Ophthalmology 113:2310–2316, doi:10.1016/j.ophtha.2006.05.067

    Article  PubMed  Google Scholar 

  4. Giovannini A, Neri P, Mercanti L, Brue C (2007) Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation. Br J Ophthalmol 91:620–623, doi:10.1136/bjo.2006.103135

    Article  PubMed  Google Scholar 

  5. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester JV (2005) Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 89:147–150, doi:10.1136/bjo.2004.046623

    Article  PubMed  CAS  Google Scholar 

  6. Nowilaty SR, Bouhaimed M (2006) Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 90:982–986, doi:10.1136/bjo.2006.091538

    Article  PubMed  CAS  Google Scholar 

  7. Parodi MB, Iacono P, Spasse S, Ravalico G (2006) Photodynamic therapy for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 141:123–128, doi:10.1016/j.ajo.2005.07.045

    Article  PubMed  Google Scholar 

  8. Brown DM, Regillo CD (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627–637, doi:10.1016/j.ajo.2007.06.039

    Article  PubMed  CAS  Google Scholar 

  9. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439–444, doi:10.1097/IAE.0b013e31804b3e15

    Article  PubMed  Google Scholar 

  10. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A et al (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27:707–712

    PubMed  Google Scholar 

  11. Rinaldi M, Dell’Omo R, Romano MR, Chiosi F, Cipollone U, Costagliola C (2007) Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol 125:1422–1423, doi:10.1001/archopht.125.10.1422

    Article  PubMed  Google Scholar 

  12. Mandal S, Garg S, Venkatesh P, Mithal C, Vohra R, Mehrotra A (2007) Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 125:1487–1492, doi:10.1001/archopht.125.11.1487

    Article  PubMed  CAS  Google Scholar 

  13. Gomi F, Nishida K, Oshima Y, Sakaguchi H, Sawa M, Tsujikawa M et al (2007) Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol 143:507–510, doi:10.1016/j.ajo.2006.10.050

    Article  PubMed  CAS  Google Scholar 

  14. Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143:977–983, doi:10.1016/j.ajo.2007.02.039

    Article  PubMed  CAS  Google Scholar 

  15. Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP (2007) Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27:1180–1186

    Article  PubMed  Google Scholar 

  16. Macular Photocoagulation Study Group (1987) Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Arch Ophthalmol 105:1499–1507

    Google Scholar 

  17. Morgan CM, Schatz H (1986) Recurrent multifocal choroiditis. Ophthalmology 93:1138–1147

    PubMed  CAS  Google Scholar 

  18. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L et al (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131:647–652, doi:10.1016/S0002–9394(01)00925–4

    Article  PubMed  CAS  Google Scholar 

  19. Lim WK, Buggage RR, Nussenblatt RB (2005) Serpiginous choroiditis. Surv Ophthalmol 50:231–244, doi:10.1016/j.survophthal.2005.02.010

    Article  PubMed  Google Scholar 

  20. Dees C, Arnold JJ, Forrester JV, Dick AD (1998) Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol 116:1456–1461

    PubMed  CAS  Google Scholar 

  21. Fine SL, Wood WJ, Isernhagen RD, Singerman LJ, Bressler NM, Folk JC et al (1993) Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: results of a pilot randomized clinical trial. Arch Ophthalmol 111:19–20

    PubMed  CAS  Google Scholar 

  22. Essex RW, Tufail A, Bunce C, Aylward GW (2007) Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br J Ophthalmol 91:649–654, doi:10.1136/bjo.2005.089458

    Article  PubMed  Google Scholar 

  23. Rogers AH, Duker JS, Nichols N, Baker BJ (2003) Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 110:1315–1320, doi:10.1016/S0161–6420(03)00466–4

    Article  PubMed  Google Scholar 

  24. Spaide RF, Freund KB, Slakter J, Sorenson J, Yannuzzi LA, Fisher Y (2002) Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22:545–549, doi:10.1097/00006982–200210000–00003

    Article  PubMed  Google Scholar 

  25. Borkowski LM, Weinberg DV, Delany CM, Milsow L (2001) Laser photocoagulation for choroidal neovascularization associated with sympathetic ophthalmia. Am J Ophthalmol 132:585–587, doi:10.1016/S0002–9394(01)01044–3

    Article  PubMed  CAS  Google Scholar 

  26. Bom S, Young S, Gregor Z, Lightman S (2002) Surgery for choroidal neovascularization in sympathetic opthalmia. Retina 22:109–111, doi:10.1097/00006982–200202000–00021

    Article  PubMed  Google Scholar 

  27. Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS (2008) Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina 28:71–80

    Article  PubMed  Google Scholar 

  28. Farah ME, Costa RA, Muccioli C, Guia TA, Belfort R (2002) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 134:137–139, doi:10.1016/S0002–9394(02)01456–3

    Article  PubMed  Google Scholar 

  29. Kinge B, Syrdalen P, Bjornsson OM (2005) Photodynamic therapy for choroidal neovascularization secondary to sympathetic ophthalmia. Retina 25:375–377, doi:10.1097/00006982–200504000–00023

    Article  PubMed  Google Scholar 

  30. Kuo IC, Rechdouni A, Rao NA, Johnston RH, Margolis TP, Cunningham ET (2000) Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease. Ophthalmology 107:1721–1728, doi:10.1016/S0161–6420(00)00244-X

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowlegements

Acknowledgements to Pr Gérard FORZY (Université Catholique de Lille, France) for the statistical analysis support.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Groupe Hospitalier Pitié Salpêtrière, Paris, France

    Thi Ha Chau Tran, Christine Fardeau, Céline Terrada, Ghislaine Ducos De Lahitte, Bahram Bodaghi & Phuc Lehoang

  2. Department of Ophthalmology, Hôpital Saint Vincent de Paul, Boulevard Belfort BP 387, 59020, Lille Cedex, France

    Thi Ha Chau Tran

Authors
  1. Thi Ha Chau Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Fardeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Céline Terrada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ghislaine Ducos De Lahitte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bahram Bodaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Phuc Lehoang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thi Ha Chau Tran.

Additional information

None of the authors has any financial interest in this study.

The authors have full control of all primary data and agree to allow Graefe’s Archive for Clinical and Experimental Opthalmology to review the data if requested.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tran, T.H.C., Fardeau, C., Terrada, C. et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 246, 1685–1692 (2008). https://doi.org/10.1007/s00417-008-0906-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0906-4

Keywords

Search

Navigation